Merck KGaA says it can catch up in immuno-oncology with Pfizer's help

Merck KGaA, long plagued by clinical setbacks, is pushing into Phase III with a Pfizer ($PFE)-partnered cancer treatment, believing it can eventually catch up with rivals already on the market. The German company kicked off a late-stage lung cancer trial on avelumab, an antibody that blocks PD-L1 to activate immune cells, and healthcare chief Belen Garijo told Reuters the drugmaker has a plan to contend with Merck ($MRK), Bristol-Myers Squibb ($BMY) and others by pursuing trials in underserved cancer types. Pfizer bought into avelumab in a sweeping collaboration deal last year. More

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.